Drug candidates that are insoluble tend to have low bioavailability or limited absorption. One option to overcome incomplete absorption due to insolubility is to utilize an amorphous solid dispersion (ASD). This option is advantageous because ASDs allow for improved exposure and solubility rates compared to conventional crystalline compounds.
Amorphous dispersions are typically formed by using a polymer mixed with the compound to create a stable and scalable dispersion. Selecting the correct polymer is crucial for formulating an ASD that resists phase separation (which can lead to crystallization and slow dissolution). Our scientists will evaluate possible polymer options and select the optimal combination based on the drug to polymer ratio and the solvent used in the process.
Amorphous Solid Dispersion Screening
We can provide amorphous solid dispersion (ASD) screening to assess potential compound/polymer combinations and detect any potential risks in the resulting dispersions. Our aim is to offer clients data they need to make informed decisions on polymer selection and the next step in the development process.
VxP Pharma manufacturing services offer flexibility for a wide variety of solid dispersion forms and provide consistency in the final product that your project requires. With so many resources at your disposal, VxP Pharma can seamlessly tailor the specifications and packaging of your solid dispersion to suit your specific needs. Support from our manufacturing staff and development experts will ensure you quickly receive the best formulation of your drug candidate. It’s our goal to provide you with the manufacturing resources and analytical capabilities to keep your pharmaceutical manufacturing project on time and on budget. We offer a full range of solid dispersion assessment and manufacturing services.
Our state-of-the-art labs are staffed by some of the best trained and most experienced subject matter experts in the field.